search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Then, we succeeded to alleviate this by a powerful synergistic


formula that acted on several lev- els. Lumance (Innovad, NV/SA Belgium) is a complex formula, combining slow release and pro-


tection technologies ensuring that fatty acids, essential oils, plant ex- tracts, and anti-inflammatory compounds and polyphenols are delivered in a gut active way.


In our research, we are aiming to study the impact of this product on 1) Anti-inflammatory and Antioxi- dant activity both at gut tissue (cyto-


protective) and blood (systemic) level 2) gut barrier function 3) Immunomodulation


(both cytoprotective and systemic) and 4) (im- mune)-metabolic modulation. To provide a challenge, in


the present experiment, a high amount of wheat and rye with no coccidiostats and NSP hydrolysing enzymes were used in any of the experimental diets. The experiment is a completely randomised design of treatments with Lumance at three different concentrations (0, 1, and 2 kg/ ton) in the feed. Growth parameters were deter- mined during the experiment and the anti-in- flammatory effect of the dietary treatments was measured by the jejunal level of the pro-inflammatory


cytokine (Interferon-gamma (IFNγ)), and as well as that of Malonylaldehyde (MDA) on day 28 with the immune and bio- chemical assays. A total of 540 male broiler chickens (Ross 308), aged 1d old, of similar mean body weight vaccinated for Newcastle dis- ease, were used in this study. The effects of the three dietary treatments on BW, FI, and FCR are summarised in Table 1. Overall, Lumance linearly enhanced BW significantly at 35d. Supplementation of Lumance with 1 and 2 kg/ton increased the body weight of broilers by 3.6 % and 6 % respectively, compared to the control. Concerning the feed conversion ra- tio over 0–5 weeks, treated chicks significantly improved the FCR. Regarding the feed intake, no differences were observed between the treatments over the 5 weeks. Mortality was not significantly associated with treatment but was mostly asso- ciated with the typical symptoms of coccidiosis.


Immune response It is well established that stress regardless of its origin or na- ture leads to inflammation and the release of pro-inflamma- tory cytokines. Cytokines activate immune cells and have a profound detrimental effect on growth performance. It was shown that broilers consuming wheat and rye-based diet for 20 days increased the systemic level of pro-inflammato- ry cytokine (IFNγ) which contributed to an increase in


Table 1 – Effect of Lumance on performance indices of broilers at different ages.


Variable 0


Body Weight (kg) 14 d 28 d 35 d FCR


0-14 d


14-28 d 29-35 d 0-35 d


Feed intake (kg) 0-14 d


14-28 d 29-35 d 0-35 d


0.42 ± 0.015 1.15 ± 0.036 1.73 ± 0.063


0.95 ± 0.043 1.86 ± 0.098 1.90 ± 0.132 1.65 ± 0.035


0.40 ± 0.025 1.34 ± 0.076 1.12 ± 0.055 2.86 ± 0.066


Dietary Lumance (kg/ton) 1


0.43 ± 0.018 1.17 ± 0.530 1.8 ± 0.070


0.93 ± 0.042 1.80 ± 0.160 1.80 ± 0.143 1.59 ± 0.092


0.39 ± 0.019 1.35 ± 0.199 1.12 ± 0.090 2.87 ± 0.252


Mean values ± SD are reported Each mean represents values from 6 replicates (30 birds/replicate) P-value: Linear regression between Dietary Lumance 2, 1 and 0 (kg/ton)


inflammation. Non-starch polysaccharides, together with re- sistant starch and lignin, form the whole of dietary fibre of wheat and rye, has been reported to exhibit multiple biologi- cal functions that can induce intestinal chronic inflammation. Our preliminary findings show that the intestinal concentra- tion of the pro-inflammatory cytokine Interferon-gamma (IFNγ), was significantly affected by the dietary treatments. Treated birds exhibited a lower pro-inflammatory cytokines IFNγ at d 28 compared with none supplemented birds (Figure 1A). These results are consistent with what we expected from its anti-inflammatory activity and it is well correlated with our previous in-vitro finding. Reduction in cytokine synthesis dur- ing inflammation is thought to be a major mechanism by which this complex reduces inflammation. Malondialdehyde is a lipid peroxidation product, and. MDA content can, there- fore, be an indicator of membrane injury and oxidative stress. ROS-induced lipid peroxidation triggers inflammation and generates cytokines. For malondialdehyde (MDA), a linear de- crease in jejunal expression was found in treated chicks com- pared to the control group (Figure 1B).


Ongoing work In conclusion, Lumance could reduce the chronic intestinal inflammation and counteract the synergistic and additive negative impact of several stress factors, typically seen in the field. However, there is a clear need to identify other biomarkers of intestinal inflammation. Our work is ongoing and we are aiming to test and look at other important intestinal biomarkers.


▶ GUT HEALTH | DECEMBER 2020 35 P-value 2


0.44 ± 0.014 1.20 ± 0.043 1.87 ± 0.141


0.25


0.051 0.038


0.91 ± 0.069w 0.247 1.73 ± 0.096 1.75 ± 0.166 1.55 ± 0.047


0.39 ± 0.041 1.32 ± 0.56 1.16 ± 0.104 2.89 ± 0.178


0.119 0.121 0.019


0.766 0.907 0.417 0.798


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124